Prior research has primarily concentrated on clinical prognosis and has pointed out that overexpression of SLC2A3 is prominently associated with worse prognosis, such as increased depth of invasion, larger tumor size, advanced pathological stage, recurrence, and vascular embolization [6]. The gene discussed is SLC2A3; the disease is neoplasm.